4,901 trials
Healthy
Primary: Part A, B and C: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Tepotinib — 16146; 18645; 12609; 23457…
Sleep Apnea, Obstructive · Pulmonary Disease, Chronic Obstructive · Respiration Disorders
Primary: OSA Cohort: Apnea-Hypopnea Index (AHI) on Day 8 of Treatment Periods 1 and 2 — 45.09; 44.90 events (apnea plus hyponea) per hour
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib — 44240; 45740 ng/mL (nanogram/milliliter)
Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MK-8189 — 5600; 4710 h*nmol/L
Cocaine Dependence
Primary: Regional Availability of Metabotropic Glutamate Type-5 Receptors (mGluR5) — 36.48; 32.19; 25.67; 22.41 mL*cm^3 — p=0.035
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-07321332 — 43360; 35860 Nanogram*hour…
Healthy Participants
Primary: Maximum Plasma Concentration (Cmax) of Midazolam When Administered Alone and With PF-07321332/Ritonavir — 9.812; 36.18 ng/mL
Type 1 Diabetes Mellitus
Primary: Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas — 3.4; 2.0; 1.8; 1.9 millimeter
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 400 Milligram (mg)
Healthy Volunteers
Primary: Part 1, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Itraconazole — 1310; 1527 nanogram per milliliter (ng/mL)
Healthy
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Ethinyl Estradiol — 812.3; 823.9…
Idiopathic Hypersomnia
Primary: Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) — 14.8; 40.0 percentage of participants
Healthy Volunteers
Primary: Area Under the Concentration (AUC 72) — 37434.51; 33716.80 pg.h/mL
Alzheimer's Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Advanced Breast Carcinoma · Advanced Malignant Solid Neoplasm · Advanced Prostate Carcinoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 2; 0; 0; 0 Participants